Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

September 22, 2020

Primary Completion Date

June 30, 2021

Study Completion Date

March 1, 2022

Conditions
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaSmall Lymphocytic LeukemiaMarginal Zone Lymphoma
Interventions
DRUG

Acalabrutinib

Acalabrutinib 100 mg capsules taken by mouth every 12 hours (PO BID), for a total of 2 daily doses on Days 1 to 21 of each cycle.

DRUG

Rituximab

Rituximab 375 mg/m2 administered intravenously (IV) on Day 1 of each cycle.

DRUG

Ifosfamide

Ifosfamide 5g/m2 administered intravenously (IV) over 24 hours on Day 2 of each cycle.

DRUG

Carboplatin

Carboplatin Area Under the Concentration time Curve (AUC) 5 IV administered intravenously (IV) on Day 2 of each cycle.

DRUG

Etoposide

Etoposide 100 mg/m2 administered intravenously (IV) on Days 1, 2 and 3 of each cycle.

Trial Locations (1)

33136

University of Miami, Miami

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

University of Miami

OTHER